# DEA Schedules 4 New Synthetic Opioids to Schedule I Amid Safety Concerns

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/dea-schedules-4-new-synthetic-opioids-to-schedule-i-amid-safety-concerns/
> **Published:** 2026-09-19T17:01:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-19T17:01:25-04:00
> **Clinical Summary:** ⚖️ Policy Watch • Justice Department Executive Regulatory Brief The US Department of Justice’s Drug Enforcement Administration has issued a temporary order scheduling four new synthetic opioids, including 5,6-dichloro brorphine and spirochlorphine, as Schedule I controlled substances under the Controlled Substances Act. This move aims to prevent an imminent hazard to public safety by imposing […]

---

⚖️ Policy Watch • Justice Department
 
 
 Executive Regulatory Brief
 

The US Department of Justice’s Drug Enforcement Administration has issued a temporary order scheduling four new synthetic opioids, including 5,6-dichloro brorphine and spirochlorphine, as Schedule I controlled substances under the Controlled Substances Act. This move aims to prevent an imminent hazard to public safety by imposing strict regulatory controls on these substances. The DEA’s action takes effect immediately.

 Docket / Citation: [Federal Register (2026-08-27)](https://www.federalregister.gov/documents/2026/08/27/2026-17531/schedules-of-controlled-substances-temporary-placement-of-56-dichloro-brorphine-56-dichloro)
 
 
 

### Clinical & Patient Impact

 

Shifts in federal policy directly impact patient safety standards and therapeutic availability.

 
 📌 Dr. Caplan’s Perspective: “Physicians must remain vigilant about the rapidly evolving landscape of controlled substances, adapting their practices accordingly to ensure patient safety and access to necessary treatments.”
 
 

 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 
 Physician-Led, Whole-Person Care
 A doctor who takes the time to truly understand you.
 Personal care that starts with listening and is guided by experience and ingenuity.
 
 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Cannabis Consultation](https://cedclinic.com/book/)
 
 
 
 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 
 

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).